Different Histological Classifications for Henoch-Schönlein Purpura Nephritis: Which One Should Be Used?

Overview

Journal Pediatr Rheumatol Online J

Publisher Biomed Central

Specialty Pediatrics

Date 2019 Mar 2

PMID 30819179

Citations 37

Authors

Marija Jelusic

Mario Sestan

Rolando Cimaz

Seza Ozen

Affiliations

Soon will be listed here.

Abstract

Background: Nephritis is the most important chronic complication of IgA Vasculitis (IgAV)/Henoch-Schönlein purpura (IGAV/HSP) and thus the main prognostic factor of this most common childhood vasculitis. Since the prognosis and treatment selection depends on the mode of interpretation of biopsy material, in this manuscript we have presented several issues related to the uneven application of different histological classifications in IgAV/Henoch-Schönlein purpura nephritis (HSPN). The nephritis of IgAV/IGAV/HSP will be abbreviated as HSPN for this paper.

Main Body: In clinical practice we use different histological classifications for HSPN. It is not known which of these classifications best correlates with severity of renal disease and renal outcome in IgAV/IGAV/HSP. One of the major problem with existing histological classifications is that there is no consensus on the implementation of biopsy in the treatment of HSPN. There is a histologic classification system conventionally used in HSPN, of the International Study of Kidney Disease in Children (ISKDC). On the other hand there is the new classification system suggested for IgA nephropathy, the Oxford classification. The latter has been validated only in IgA nephropathy. There are also two further histologic classifications of Haas and Koskela that have been developed. Current treatment strategies in HSPN are not standardised nor predominantly based on histological classification.

Conclusion: One of the possible solutions to problems related to the application of different histological classification in HSPN is the implementation of multicenter multinational prospective studies with joint collaboration between pediatric rheumatologists, nephrologists and nephropathologists to correlate the clinical features and outcome with the classification systems as well among the classifications. This classification should be the basis for the construction of guidelines for the treatment of patients with HSPN.

Citing Articles

Analysis of the influencing factors of abdominal Henoch-Schonlein purpura in children with gastrointestinal bleeding and the clinical value of PLR.

Yang X, Lu R, Liu Q, Zhang J, Yan H, Lu H Am J Transl Res. 2024; 16(8):3867-3874.

PMID: 39262691 PMC: 11384381. DOI: 10.62347/NNRB3322.

The efficacy of rituximab in the treatment of IgA vasculitis nephritis.

Xiong Y, Cuevas S, Xu G, Zou H Clin Exp Med. 2024; 24(1):213.

PMID: 39249581 PMC: 11383840. DOI: 10.1007/s10238-024-01461-6.

Navigating Adult-Onset IgA Vasculitis-Associated Nephritis.

Gan M, Chua F, Chang Z, Chua Y, Chan G Life (Basel). 2024; 14(8).

PMID: 39202674 PMC: 11355272. DOI: 10.3390/life14080930.

Clinicopathological features and prognosis of IgA vasculitis nephritis with nephrotic-range proteinuria in children.

Xi L, Sun Y, Chen Y, Yang X, Su H, Ren X Pediatr Nephrol. 2024; 39(11):3241-3250.

PMID: 38980322 DOI: 10.1007/s00467-024-06441-2.

The efficacy and safety of tacrolimus in treating refractory IgA vasculitis nephritis: a single-center retrospective study on 16 cases.

Gan Y, Chen J, Wang M, Li Q, Wang A, Yang H Clin Kidney J. 2024; 17(5):sfae115.

PMID: 38742208 PMC: 11089412. DOI: 10.1093/ckj/sfae115.

References

Rai A, Nast C, Adler S . Henoch-Schönlein purpura nephritis. J Am Soc Nephrol. 1999; 10(12):2637-44. DOI: 10.1681/ASN.V10122637. View

Scharer K, Krmar R, Querfeld U, Ruder H, Waldherr R, Schaefer F . Clinical outcome of Schönlein-Henoch purpura nephritis in children. Pediatr Nephrol. 1999; 13(9):816-23. DOI: 10.1007/s004670050707. View

Daniel L, Saingra Y, Giorgi R, Bouvier C, Pellissier J, Berland Y . Tubular lesions determine prognosis of IgA nephropathy. Am J Kidney Dis. 2000; 35(1):13-20. DOI: 10.1016/S0272-6386(00)70295-2. View

Foster B, Bernard C, DRUMMOND K, Sharma A . Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr. 2000; 136(3):370-5. DOI: 10.1067/mpd.2000.103448. View

Davin J, ten Berge I, Weening J . What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis?. Kidney Int. 2001; 59(3):823-34. DOI: 10.1046/j.1523-1755.2001.059003823.x. View

Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D . Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002; 13(5):1271-8. DOI: 10.1097/01.asn.0000013883.99976.22. View

Rauta V, Tornroth T, Gronhagen-Riska C . Henoch-Schoenlein nephritis in adults-clinical features and outcomes in Finnish patients. Clin Nephrol. 2002; 58(1):1-8. DOI: 10.5414/cnp58001. View

Ronkainen J, Nuutinen M, Koskimies O . The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet. 2002; 360(9334):666-70. DOI: 10.1016/S0140-6736(02)09835-5. View

Gardner-Medwin J, Dolezalova P, Cummins C, Southwood T . Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002; 360(9341):1197-202. DOI: 10.1016/S0140-6736(02)11279-7. View

10.

Ronkainen J, Ala-Houhala M, Huttunen N, Jahnukainen T, KOSKIMIES O, Ormala T . Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria. Clin Nephrol. 2003; 60(2):80-4. DOI: 10.5414/cnp60080. View

11.

Goldstein A, White R, Akuse R, Chantler C . Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet. 1992; 339(8788):280-2. DOI: 10.1016/0140-6736(92)91341-5. View

12.

Tarshish P, Bernstein J, Edelmann Jr C . Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol. 2003; 19(1):51-6. DOI: 10.1007/s00467-003-1315-x. View

13.

Weening J, DAgati V, Schwartz M, Seshan S, Alpers C, Appel G . The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004; 65(2):521-30. DOI: 10.1111/j.1523-1755.2004.00443.x. View

14.

Yang Y, Hung C, Hsu C, Wang L, Chuang Y, Lin Y . A nationwide survey on epidemiological characteristics of childhood Henoch-Schönlein purpura in Taiwan. Rheumatology (Oxford). 2005; 44(5):618-22. DOI: 10.1093/rheumatology/keh544. View

15.

Narchi H . Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005; 90(9):916-20. PMC: 1720564. DOI: 10.1136/adc.2005.074641. View

16.

Okada H, Suzuki H, Konishi K, Sakaguchi H, Saruta T . Histological alterations in renal specimens as indicators of prognosis of IgA nephropathy. Clin Nephrol. 1992; 37(5):235-8. View

17.

Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L . Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am J Kidney Dis. 2006; 47(6):993-1003. DOI: 10.1053/j.ajkd.2006.02.178. View

18.

de Almeida J, Campos L, Paim L, Leone C, Koch V, Silva C . Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of initial prognostic factors. J Pediatr (Rio J). 2007; 83(3):259-66. DOI: 10.2223/JPED.1638. View

19.

Butani L, Morgenstern B . Long-term outcome in children after Henoch-Schonlein purpura nephritis. Clin Pediatr (Phila). 2007; 46(6):505-11. DOI: 10.1177/0009922806298896. View

20.

Lucas Garcia J, Alvarez Blanco O, Sanahuja Ibanez M, Ortega Lopez P, Zamora Martin I . [Outcome of Henoch-Schönlein nephropathy in pediatric patients. Prognostic factors]. Nefrologia. 2008; 28(6):627-32. View